Benchmarking of Mutation Diagnostics in Clinical Lung Cancer Specimens

Benchmarking of Mutation Diagnostics in Clinical Lung Cancer Specimens

Treatment of EGFR-mutant non-small cell lung cancer patients with the tyrosine kinase inhibitors erlotinib or gefitinib results in high response rates and prolonged progression-free survival. Despite the development of sensitive mutation detection approaches, a thorough validation of these in a clin...

Full description

Bibliographic Details
Main Authors: Querings, Silvia, Altmüller, Janine, Ansén, Sascha, Zander, Thomas, Seidel, Danila, Gabler, Franziska, Peifer, Martin, Markert, Eva, Stemshorn, Kathryn, Timmermann, Bernd, Saal, Beate, Klose, Stefan, Ernestus, Karen, Scheffler, Matthias, Engel-Riedel, Walburga, Stoelben, Erich, Brambilla, Elisabeth, Wolf, Jürgen, Nürnberg, Peter, Thomas, Roman K.
Format: Online
Language:English
Published: Public Library of Science 2011
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3088700/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3088700/

Similar Items